Global Yuviwel Patent Settlement
Ascendis and BioMarin resolve all global patent disputes regarding Yuviwel with a new licensing agreement.
Anonymous
Key Points
1
The royalty arrangement extends beyond the U.S., with an 18% royalty applying to the European Union, Brazil, and South Korea through May 2030, in addition to the 20% U.S. royalty.
2
The license scope covers current and potential future indications, as well as combination use and other applications connected to Yuviwel that involve BioMarin's CNP technology.
3
As part of the global settlement, the parties resolve a U.S. ITC investigation and litigation across multiple countries related to Yuviwel.
4
TransCon CNP (navepegritide) is described as a weekly prodrug of CNP that provides continuous exposure to receptors to counteract FGFR3 signaling in achondroplasia.
5
Ascendis’ leadership projects substantial long-term financial potential from the deal, including more than €500 million in operating cash flow in 2026 and approximately €5 billion in revenue by 2030.
Ascendis Pharma and BioMarin have resolved their global patent disputes over Yuviwel through a binding settlement and license agreement Benzinga. Under the deal, Ascendis gains a worldwide, non-exclusive license to continue developing and selling the drug while BioMarin receives royalties of 20% on U.S. net sales and 18% on European Union, Brazil, and South Korea sales through May 2030 TipRanks.
The settlement ends ongoing litigation across multiple countries and resolves a U.S. International Trade Commission investigation Investing.com. BioMarin's stock jumped 5% following the announcement. Ascendis projects the deal could generate more than €500 million in operating cash flow by 2026 and approximately €5 billion in revenue by 2030 Post Register.
What the Settlement Covers and Why It Matters
The agreement resolves all patent disputes related to Yuviwel and navepegritide, Ascendis's development candidates Benzinga. The license scope includes current indications plus future uses involving BioMarin's CNP (C-type natriuretic peptide) technology. This broad coverage means Ascendis can pursue combination therapies and new applications without future patent conflicts TipRanks.
How the Royalty Structure Works Globally
Ascendis will pay BioMarin 20% royalties on net Yuviwel sales in the United States Investing.com. In the European Union, Brazil, and South Korea, the royalty rate drops to 18%. Both royalty streams continue through May 2030, aligning Ascendis's payments with defined market timelines Post Register. The tiered structure reflects regional revenue differences and market conditions.
Why Yuviwel Matters for Achondroplasia Treatment
Yuviwel uses BioMarin's CNP technology, which targets FGFR3 signaling to help patients with achondroplasia, a rare genetic disorder affecting bone growth TipRanks. The drug is a weekly prodrug that provides continuous exposure to counteract abnormal growth signals. Ascendis's financial projections suggest strong commercial potential once the drug reaches full market scale Post Register.
End of Legal Battles Unlocks Development Path
Both companies faced ongoing litigation and an ITC investigation that created uncertainty around Yuviwel's future Benzinga. The settlement eliminates these legal roadblocks and provides BioMarin a covenant not to sue, protecting both parties from future claims. Market analysts view the deal as a win-win: Ascendis gains clear rights to commercialize, and BioMarin receives royalty income without litigation costs Investing.com.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
14
Articles
36
Reach
50
Topics
A
AnonymousAuthor
